Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Eiji Nakano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Melanoma, GTP Phosphohydrolases, Membrane Proteins, Benzimidazoles. Die Arbeit nennt 14 Literaturangaben. Gefördert von: the National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
NRAS mutations represent the second most common genetic alteration in melanoma and are associated with aggressive disease and limited treatment options. While MEK inhibitors have shown clinical benefit in patients with NRAS ‐mutant melanoma in clinical trials, real‐world data in Asian populations remain limited. We conducted a retrospective analysis of patients with advanced NRAS ‐mutant melanoma treated with binimetinib at the National Cancer Center Hospital. NRAS mutations were confirmed via comprehensive genomic profiling. Fifteen patients were included, with a median age of 66 years. Most had mucosal melanoma (80.0%), and NRAS mutations at codons 12, 13, and 61 were seen in seven, one, and seven patients, respectively. One patient (6.7%) achieved a partial response, and eight (53.3%) had stable disease, resulting in a disease control rate of 60.0%. The median PFS was 3.1 months (95% confidence intervals, 1.5–4.6), and the median OS was 4.8 months (95% confidence intervals, 1.8–8.8). Fourteen patients (93.3%) experienced at least one adverse event (AE), with skin rash being the most common. Grade ≥ 3 AEs occurred in 4 patients (26.7%), and 8 (53.5%) required dose interruption. Binimetinib demonstrated modest clinical activity and manageable safety in Japanese patients with advanced NRAS ‐mutant melanoma, with outcomes comparable to those observed in Western populations. This study is limited by its retrospective design and small sample size, warranting cautious interpretation of results. These findings provide supportive evidence for the use of binimetinib in patients with NRAS ‐mutant melanoma following immune checkpoint inhibitor failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Eiji Nakano, Dai Ogata, Naoya Yamazaki, Kenjiro Namikawa
Förderung
- the National Cancer Center Research and Development Fund
Zitieren
APA
Nakano, E., Kage, Y., Ogata, D., Yamazaki, N., & Namikawa, K. (2025). Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70009
Vancouver
Nakano E, Kage Y, Ogata D, Yamazaki N, Namikawa K. Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.70009
BibTeX
@article{Nakano2025,
author = {Nakano, Eiji and Kage, Yuta and Ogata, Dai and Yamazaki, Naoya and Namikawa, Kenjiro},
title = {Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.70009}
}
EUVIMED